Inhibrx Biosciences, Inc. (INBX)
Healthcare
Biotechnology
82.10 $
-3.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Inhibrx Biosciences, Inc. (INBX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 57.0% of the shares are freely tradable; institutional investors hold 83.1%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
83.1%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
23.2%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
57.0%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
31.3%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
15Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Perceptive Advisors LLC | 9.83 | 1,442,707 | -0.7 | 03/31/2026 |
| Viking Global Investors LP | 9.80 | 1,437,705 | +0.0 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 8.61 | 1,263,078 | +8.2 | 03/31/2026 |
| Sanofi | 7.89 | 1,157,926 | +0.0 | 06/30/2026 |
| HighTower Advisors, LLC | 5.93 | 870,200 | +0.0 | 03/31/2026 |
| BlackRock Inc | 5.45 | 798,898 | +2.8 | 03/31/2026 |
| State Street Corp | 3.75 | 550,845 | +46.9 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.32 | 486,422 | +0.0 | 03/31/2026 |
| Sofinnova Ventures | 2.77 | 406,029 | -10.7 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 2.71 | 397,878 | +0.6 | 07/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.